

Multinational pharmaceutical company— Defense steering committee in acid reflux multi- district litigation

10.15.2019

Secured an order granting our motion to exclude plaintiffs' expert testimony, and then successfully moved for summary judgment, resulting in the dismissal of all remaining plaintiffs in an MDL involving claims that a pharmaceutical innovator's acid reflux treatment drug caused bone fractures.